Active — Not RecruitingNot Applicable

Brain Oligometastasis in NSCLC

France46 participantsStarted 2025-01-01

Plain-language summary

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Consecutive patients managed at Bordeaux University Hospital * Non-small-cell lung cancer * Oligometastatic brain cancer (fewer than 5 lesions at diagnosis) * Patient over 18 years old Exclusion Criteria: * Oncogenic addiction EGFR, ALK, ROS1 * Patient with concomitant cancer * Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage

What they're measuring

Progression free survival (PFS)

Timeframe: Once, at progression or death from any cause

Trial details

NCT IDNCT07389642

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03

View on ClinicalTrials.gov More Brain Oligometastatic trials